Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma, Non-Hodgkin 12Myelodysplastic Syndromes 11Recurrence 7Leukemia, Myelomonocytic, Chronic 7Anemia, Refractory, with Excess of Blasts 7Leukemia, Biphenotypic, Acute 6Multiple Myeloma 5Lymphoma, Follicular 5Lymphoma 5Hodgkin Disease 5Hematologic Neoplasms 5Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Burkitt Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma, B-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Breast Neoplasms 3Blastic Plasmacytoid Dendritic Cell Neoplasm 3Uveal Melanoma 2Triple Negative Breast Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms, Germ Cell and Embryonal 2

Interventions

fludarabine phosphate 1Specimen Handling 1Leukapheresis 1Cyclophosphamide 1Blood Component Removal 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Prolymphocytic, B-Cell × fludarabine phosphate × Clear all
NCT05418088 2026-05-29

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡